Correlation between peripheral blood and bone marrow regarding flt3-itd and npm1 mutational status in patients with acute myeloid leukemia

Haematologica

Volumn 100, Issue 3, 2015, Pages e97-e98

  Tong, Wei Gang ^a   Sandhu, Vicky K ^b   Wood, Brent L ^a,b   Hendrie, Paul C ^a,b   Becker, Pamela S ^a,b   Pagel, John M ^a,b   Walter, Roland B ^a,b   Estey, Elihu H ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

Author keywords

Acute myeloid leukemia; FLT3 ITD; Mutations; NPM1 peripheral blood bone marrow

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; BLOOD; BONE MARROW; CORRELATION COEFFICIENT; CYTOGENETICS; FLT3 ITD GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE MUTATION; GENETIC PROCEDURES; HUMAN; INTERNAL TANDEM DUPLICATION; LETTER; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; NPM1 GENE; SENSITIVITY AND SPECIFICITY; GENE EXPRESSION; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MONONUCLEAR CELL; MUTATION; PATHOLOGY; TANDEM REPEAT;

CD135 ANTIGEN; FLT3 PROTEIN, HUMAN; NUCLEAR PROTEIN; NUCLEOPHOSMIN;

BONE MARROW; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES, MONONUCLEAR; MUTATION; NUCLEAR PROTEINS; TANDEM REPEAT SEQUENCES;

EID: 84924655425     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.118422     Document Type: Letter

References (10)

1. Weinkauff R, Estey EH, Starostik P, et al. Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia. Am J Clin Pathol. 1999;111(6):733-740.
2. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079-1089.
3. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909-1918.
4. Kiyoi H, Naoe T. Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation. Int J Hematol. 2006; 83(4):301-308.
5. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224-234.
6. Sausen M, Parpart S, Diaz LA Jr. Circulating tumor DNA moves further into the spotlight. Genome Med. 2014;6(5):35-38.
7. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28-37.
8. Lo-Coco F, Breccia M, Diverio D. The importance of molecular monitoring in acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 2003;16(3):503-520.
9. Jilani I, Estey E, Manshuri T, et al. Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA. Leukemia. 2003;17(1):114-119.
10. Hussein K, Ketterling RP, Hulshizer RL, et al. Peripheral blood cytogenetic studies in hematological neoplasms: predictors of obtaining metaphases for analysis. Eur J Haematol. 2008;80(4):318-321.